Clinical Trials · NCT07497503

A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants

Phase
Phase 1
Recruitment status
Recruiting
Sponsor
Syneos Health
Enrollment
48
Start date
Apr 2026
Locations
1 site, Australia
Primary endpoint
Maximum Plasma Concentration (Cmax) of B-3E07
View Teriparatide compound reference